

AMENDMENTS TO THE CLAIMS

- 1-8. (cancelled)
9. (currently amended) A spontaneously dispersible pharmaceutical composition for oral administration comprising
- (a) up to 20% by weight of N-benzoyl-staurosporine,
 - (b) 5 to 50% by weight of a hydrophilic component,
 - (c) 5 to ~~840~~ 80% of a surfactant or surfactant mixture,
 - (d) 5 to 85% of a lipophilic component, and
 - (e) 0.05 to 5% of an additive.
10. (withdrawn) A method of treatment for treating subjects in need of N-benzoyl-staurosporine therapy comprising administering a dispersible pharmaceutical composition according to claim 1 to a subject in need of such treatment.
11. (currently amended) A pharmaceutical composition according to claim 9 wherein said composition provides in a subject which has been been dosed said oral composition, for oral administration comprising N-benzoylstaurosporine and having
- (a) a variability of bioavailability levels of N-benzoylstaurosporine of from 5 to 17%;
 - (b) an AUC (0-48h)/dose value (in (h·nmol/L)/(mg/kg)) of from 380 to 2000, or
 - (c) a C_{max} dose value (in (nmol/L)/(mg/kg)) of from 60 to 310, upon administration of a dose (in mg/kg) of N-benzoylstaurosporine.
12. (withdrawn) A method of increasing bioavailability levels or reducing variability of bioavailability levels of N-benzoylstaurosporine by mixing N-benzoylstaurosporine with a carrier comprising a hydrophilic component, and a surfactant,
13. (withdrawn) A method of increasing bioavailability levels or reducing variability of bioavailability levels of N-benzoylstaurosporine, said method comprising orally administering a composition according to claim 1 to fasted beagle dogs.